Over the past 5 years, a new generation of highly potent and broadly neutralizing HIV-1 antibodies has been identified. These antibodies can protect against lentiviral infection in nonhuman primates (NHPs), suggesting that passive antibody transfer would prevent HIV-1 transmission in humans. To increase the protective efficacy of suchmonoclonal antibodies, we employed next-generation sequencing, computational bioinformatics, and structure-guided design to enhance the neutralization potency and breadth of VRC01, an antibody that targets the CD4 binding site of the HIV-1 envelope. One variant, VRC07-523, was 5- t
The generation of broadly neutralizing antibodies is a priority in the design of vaccines against HI...
Neutralizing antibodies have been shown to protect macaques against SHIV challenge. However, genetic...
Current human immunodeficiency virus-1 (HIV-1) vaccines elicit strain-specific neutralizing antibodi...
Strategies to combat HIV require structural knowledge of how antibodies recognize HIV envelope prote...
The HIV-1 pandemic emerged in 1981 and has devastated global health for over four decades. It has re...
Broadly neutralizing antibodies (bnAbs) can prevent lentiviral infection in nonhuman primates andmay...
Despite 30 years of effort, there is no effective vaccine for HIV-1. However, antibodies can prevent...
A completely protective vaccine against HIV has not been found, thus possible prevention/treatment o...
HIV-1 neutralizing monoclonal antibodies (MAbs) define key targets for vaccine development and are b...
Despite 30 years of effort, there is no effective vaccine for HIV-1. However, antibodies can prevent...
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals,...
Broadly neutralizing antibodies (bNAbs) represent a promising approach to prevent and treat HIV-1 in...
Neutralizing antibodies have been shown to protect macaques against SHIV challenge. However, genetic...
Abstract Novel broadly neutralizing antibodies targeting HIV-1 hold promise for their use in the pre...
Over 30 years after the emergence of HIV-1, there is no effective vaccine, and AIDS remains an impor...
The generation of broadly neutralizing antibodies is a priority in the design of vaccines against HI...
Neutralizing antibodies have been shown to protect macaques against SHIV challenge. However, genetic...
Current human immunodeficiency virus-1 (HIV-1) vaccines elicit strain-specific neutralizing antibodi...
Strategies to combat HIV require structural knowledge of how antibodies recognize HIV envelope prote...
The HIV-1 pandemic emerged in 1981 and has devastated global health for over four decades. It has re...
Broadly neutralizing antibodies (bnAbs) can prevent lentiviral infection in nonhuman primates andmay...
Despite 30 years of effort, there is no effective vaccine for HIV-1. However, antibodies can prevent...
A completely protective vaccine against HIV has not been found, thus possible prevention/treatment o...
HIV-1 neutralizing monoclonal antibodies (MAbs) define key targets for vaccine development and are b...
Despite 30 years of effort, there is no effective vaccine for HIV-1. However, antibodies can prevent...
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals,...
Broadly neutralizing antibodies (bNAbs) represent a promising approach to prevent and treat HIV-1 in...
Neutralizing antibodies have been shown to protect macaques against SHIV challenge. However, genetic...
Abstract Novel broadly neutralizing antibodies targeting HIV-1 hold promise for their use in the pre...
Over 30 years after the emergence of HIV-1, there is no effective vaccine, and AIDS remains an impor...
The generation of broadly neutralizing antibodies is a priority in the design of vaccines against HI...
Neutralizing antibodies have been shown to protect macaques against SHIV challenge. However, genetic...
Current human immunodeficiency virus-1 (HIV-1) vaccines elicit strain-specific neutralizing antibodi...